HALO · Halozyme Therapeutics
381 filings
HALO SEC Filings
Halozyme Therapeutics - 381 total filings
HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 4, 2016
- 8-K · Jan 11, 2016
- 8-K · Jan 13, 2016
- 8-K · Jan 26, 2016
- 10-K · Feb 29, 2016
- 8-K · Feb 29, 2016
- 8-K · Mar 7, 2016
- 8-K · May 6, 2016
- 10-Q · May 9, 2016
- 8-K · May 9, 2016
- 8-K · Jun 8, 2016
- 8-K · Aug 9, 2016
- 10-Q · Aug 9, 2016
- 8-K · Sep 1, 2016
- 10-Q · Nov 7, 2016
- 8-K · Nov 7, 2016
- 8-K · Dec 19, 2016
- 8-K · Jan 5, 2017
- 8-K · Jan 9, 2017
- 8-K · Jan 10, 2017
- 8-K · Feb 28, 2017
- 10-K · Feb 28, 2017
- 8-K · May 5, 2017
- 10-Q · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 19, 2017
- 8-K · Jul 5, 2017
- 8-K · Aug 8, 2017
- 10-Q · Aug 8, 2017
- 8-K · Sep 29, 2017
- 10-Q · Nov 7, 2017
- 8-K · Nov 7, 2017
- 8-K · Jan 10, 2018
- 8-K · Jan 12, 2018
- 10-K · Feb 20, 2018
- 8-K · Feb 20, 2018
- 8-K · Mar 22, 2018
- 8-K · Apr 6, 2018
- 8-K · May 2, 2018
- 8-K · May 10, 2018
- 10-Q · May 10, 2018
- 10-Q · Aug 7, 2018
- 8-K · Aug 7, 2018
- 8-K · Sep 5, 2018
- 8-K · Sep 10, 2018
- 8-K · Nov 6, 2018
- 10-Q · Nov 6, 2018
- 8-K · Nov 26, 2018
- 8-K · Dec 13, 2018
- 8-K · Jan 9, 2019
- 10-K · Feb 21, 2019
- 8-K · Feb 21, 2019
- 8-K · May 3, 2019
- 10-Q · May 7, 2019
- 8-K · May 7, 2019
- 8-K · Jun 12, 2019
- 8-K · Aug 6, 2019
- 10-Q · Aug 6, 2019
- 8-K · Sep 4, 2019
- 8-K · Nov 5, 2019
- 8-K · Nov 12, 2019
- 10-Q · Nov 12, 2019
- 8-K/A · Nov 12, 2019
- 8-K · Nov 12, 2019
- 8-K · Nov 14, 2019
- 8-K · Nov 18, 2019
- 8-K · Jan 14, 2020
- 8-K · Jan 16, 2020
- 8-K · Feb 24, 2020
- 8-K · Feb 24, 2020
- 10-K · Feb 24, 2020
- 8-K · May 4, 2020
- 10-Q · May 11, 2020
- 8-K · May 11, 2020
- 8-K · Aug 10, 2020
- 10-Q · Aug 10, 2020
- 8-K · Nov 2, 2020
- 10-Q · Nov 2, 2020
- 8-K · Jan 11, 2021
- 8-K · Jan 13, 2021
- 10-K · Feb 23, 2021
- 8-K · Feb 23, 2021
- 8-K · Feb 23, 2021
- 8-K · Feb 25, 2021
- 8-K · Mar 1, 2021
- 8-K · May 3, 2021
- 8-K · May 5, 2021
- 8-K · May 7, 2021
- 8-K · May 10, 2021
- 10-Q · May 10, 2021
- 8-K · Aug 9, 2021
- 10-Q · Aug 9, 2021
- 8-K · Nov 2, 2021
- 10-Q · Nov 2, 2021
- 8-K/A · Nov 2, 2021
- 8-K · Dec 10, 2021
- 8-K · Dec 13, 2021
- 8-K · Dec 29, 2021
- 8-K · Jan 10, 2022
- 8-K · Feb 3, 2022
- 10-K · Feb 22, 2022
- 8-K · Feb 22, 2022
- 8-K · Mar 15, 2022
- 8-K · Mar 21, 2022
- 8-K · Apr 13, 2022
- 8-K · May 6, 2022
- 10-Q · May 10, 2022
- 8-K · May 10, 2022
- 8-K · May 24, 2022
- 8-K/A · Aug 9, 2022
- 8-K · Aug 9, 2022
- 10-Q · Aug 9, 2022
- 8-K · Aug 15, 2022
- 8-K · Aug 16, 2022
- 8-K · Aug 18, 2022
- 8-K · Aug 19, 2022
- 8-K · Nov 8, 2022
- 10-Q · Nov 8, 2022
- 8-K · Jan 10, 2023
- 8-K · Feb 6, 2023
- 10-K · Feb 21, 2023
- 8-K · Feb 21, 2023
- 8-K · Feb 23, 2023
- 8-K · Mar 13, 2023
- 8-K · Mar 16, 2023
- 8-K · May 8, 2023
- 8-K · May 9, 2023
- 10-Q · May 9, 2023
- 10-Q · Aug 8, 2023
- 8-K · Aug 8, 2023
- 8-K · Sep 7, 2023
- 8-K · Nov 6, 2023
- 10-Q · Nov 6, 2023
- 8-K · Jan 17, 2024
- 10-K · Feb 20, 2024
- 8-K · Feb 20, 2024
- 8-K · Apr 26, 2024
- 10-Q · May 7, 2024
- 8-K · May 7, 2024
- 10-Q · Aug 6, 2024
- 8-K · Aug 6, 2024
- 10-Q · Oct 31, 2024
- 8-K · Oct 31, 2024
- 8-K · Jan 8, 2025
- 8-K · Feb 13, 2025
- 10-K · Feb 18, 2025
- 8-K · Feb 18, 2025
- 8-K · Mar 21, 2025
- 8-K · May 2, 2025
- 8-K · May 6, 2025
- 10-Q · May 6, 2025
- 10-Q · Aug 5, 2025
- 8-K · Aug 5, 2025
- 8-K · Oct 1, 2025
- 8-K · Oct 3, 2025
- 8-K · Oct 6, 2025
- 8-K · Oct 14, 2025
- 10-Q · Nov 3, 2025
- 8-K · Nov 3, 2025
- 8-K · Nov 5, 2025
- 8-K · Nov 7, 2025
- 8-K · Nov 12, 2025
- 8-K · Nov 24, 2025
- 8-K · Dec 8, 2025
- 8-K · Dec 9, 2025
- 8-K · Jan 28, 2026
- 8-K · Feb 17, 2026
- 10-K · Feb 17, 2026
- 8-K · Mar 12, 2026
- 8-K · Apr 24, 2026
- 8-K · Apr 30, 2026
- 8-K · May 7, 2026
- 8-K · May 11, 2026
- 10-Q · May 11, 2026
- 8-K · Jul 2, 2026
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026
- 8-K · Aug 18, 2026
- 8-K · Sep 16, 2026
- 8-K · Sep 18, 2026
- 8-K · Sep 22, 2026
- 8-K · Sep 30, 2026
- 10-Q · Nov 5, 2026
- 8-K · Nov 5, 2026
Halozyme Therapeutics 8-K Report, Financial Results (Nov 5, 2026)
Halozyme Therapeutics reported a strong third quarter of 2026, with total revenue growing 39% year-over-year to $493 million and royalty revenue increasing by 44% to $341 million. This robust performance has prompted the company to raise its full-year 2026 financial guidance across key metrics including total revenue, royalty revenue, Adjusted EBITDA, and Non-GAAP Diluted EPS. The company also highlighted significant progress in its ENHANZE® collaboration agreements, expanding partnerships with three current collaborators and advancing three ENHANZE® programs into Phase 1 clinical development. A notable legal victory was also achieved, with a Dutch patent court ruling in favor of Halozyme in an infringement case against Merck concerning its Keytruda Qlex product, leading to an injunction in several European markets. The company further strengthened its financial position by completing a $1.5 billion convertible notes offering.
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2026
Halozyme Therapeutics (HALO) reported a strong third quarter for 2026, demonstrating significant growth in revenues and robust operational performance. Total revenues surged by 44% year-over-year to $493.0 million, primarily driven by a substantial 44% increase in royalty income, reaching $341.0 million. This growth was fueled by strong sales of key partner products utilizing Halozyme's ENHANZE technology, notably VYVGART Hytrulo and DARZALEX SC. Product sales also saw a significant uplift of 46% to $137.3 million, largely attributed to increased demand for bulk rHuPH20 and continued market growth for proprietary product XYOSTED. Operating expenses increased by 45% to $198.0 million, impacted by higher cost of sales, increased amortization of intangibles due to recent acquisitions (Elektrofi and Surf Bio), and elevated research and development and SG&A expenses. Despite the rise in operating expenses, the company maintained strong profitability, with net income growing to $247.0 million, a 41% increase compared to the prior year's quarter, and diluted earnings per share rising to $2.01. The company also strengthened its financial position by issuing $1.5 billion in convertible notes in September 2026, enhancing its liquidity which stood at $1.07 billion in cash, cash equivalents, and marketable securities as of September 30, 2026. Halozyme continues to actively manage its capital structure, including ongoing share repurchase programs.
Halozyme Therapeutics 8-K Report, Executive Changes (Sep 30, 2026)
Halozyme Therapeutics, Inc. filed this Form 8-K to report under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) that James Daly was elected to the Board of Directors on September 28, 2026. Mr. Daly was elected to the class of directors whose terms end at the Company's annual meeting of stockholders in 2029, and was not initially assigned to any Board committee. As a non-employee director, Mr. Daly will receive compensation under the Company's director compensation program, as revised from time to time. The filing states that current components of that program consist of cash retainers for Board and committee service, restricted stock and stock option awards, and that these components were described in the proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026. The filing states there are no arrangements or understandings under which Mr. Daly was elected as a director, and no related person transactions between the Company and Mr. Daly.
Halozyme Therapeutics 8-K Report, Material Agreement (Sep 22, 2026)
On September 22, 2026, Halozyme Therapeutics, Inc. completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including $200.0 million issued under the initial purchasers' option. The Company received net proceeds of approximately $1,471.1 million after discounts, commissions and estimated offering expenses. The notes were sold under Section 4(a)(2) of the Securities Act and Rule 144A to qualified institutional buyers, and are unsecured obligations that rank senior to subordinated indebtedness and equally with existing unsubordinated liabilities. Interest is payable semi-annually on April 1 and October 1, beginning April 1, 2027. The Company used approximately $187.5 million of the proceeds to fund capped call transactions, which are intended to reduce potential dilution on conversion, subject to a cap price of approximately $208.39 per share. It also expects to use part of the proceeds to repurchase $151.7 million of its 0.25% convertible notes due 2027 and $220.0 million of its 1.00% convertible notes due 2028, for total repurchase costs of approximately $217.0 million and $435.5 million, respectively, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases. The notes have an initial conversion rate of 7.1509 shares per $1,000 principal amount, equivalent to a conversion price of approximately $139.84 per share, and the Company may settle conversions in cash, shares, or a combination at its election. Conversion is permitted under specified conditions, including a share price test of 130% of the conversion price and at any time from April 1, 2033 until shortly before maturity. The notes are redeemable at the Company's option on or after October 7, 2030 subject to a share price condition, and a cleanup redemption is available if less than $100.0 million remains outstanding. Holders may require repurchase at par plus accrued interest upon a fundamental change.
Halozyme Therapeutics 8-K Report, Corporate Update (Sep 18, 2026)
On September 17, 2026, Halozyme Therapeutics, Inc. priced an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due October 1, 2033. The offering was increased from the previously announced $1.05 billion, and the initial purchasers received a 13-day option to buy up to an additional $200 million of notes. The notes are senior, unsecured obligations, and the company expects to close the offering on September 22, 2026. The company expects net proceeds of approximately $1.275 billion, or approximately $1.471 billion if the option is exercised in full. The initial conversion rate is 7.1509 shares per $1,000 principal amount, equal to an initial conversion price of approximately $139.84 per share, a conversion premium of approximately 27.5% above the $109.68 closing price on September 17, 2026. The company will settle conversions in cash and, if applicable, shares, at its election. The company plans to use approximately $162.5 million of the net proceeds to fund capped call transactions, with an initial cap price of approximately $208.39 per share, a premium of approximately 90.0% above the September 17, 2026 last reported sale price. Concurrently, the company intends to repurchase $151.7 million principal amount of its 0.25% convertible senior notes due 2027 for a total cost of approximately $217.0 million, including accrued interest, and $220.0 million principal amount of its 1.00% convertible senior notes due 2028 for a total cost of approximately $435.5 million, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases or repayment. The filing notes that the note repurchases and related hedging activity by counterparties and holders could affect the market price of the common stock and the notes.
Halozyme Therapeutics 8-K Report, Corporate Update (Sep 16, 2026)
Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced on September 16, 2026 that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033. The company also expects to grant the initial purchasers a 13-day option to buy up to an additional $150 million of the notes. The notes are being offered only to qualified institutional buyers under Rule 144A, and the filing states they will be senior, unsecured obligations that accrue interest payable semi-annually and mature on October 1, 2033. Conversions will be settled in cash and, if applicable, shares of common stock, at the company's election. The initial conversion rate, interest rate and other terms will be set at pricing. Halozyme states it expects to use a portion of the net proceeds to fund the cost of capped call transactions and to repurchase portions of its outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028 through privately negotiated transactions. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases or repayment of the notes at maturity or upon early optional redemption. The filing notes that the note repurchases and related hedging activity by counterparties could affect the market price of the common stock and the notes, and the capped calls are generally expected to reduce potential dilution from conversions. The filing is a notice of a proposed offering and does not state final pricing, size of the option exercise or closing results. The accompanying press release also describes the company's ENHANZE drug delivery technology, Hypercon and Surf Bio hyperconcentration technologies, and its Hylenex and XYOSTED commercial products.
Halozyme Therapeutics 8-K Report, Executive Changes (Aug 18, 2026)
Halozyme Therapeutics, Inc. filed a Form 8-K dated August 18, 2026 under Item 5.02 to report the election of a new director. On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors. She was placed in the class of directors whose terms end at the Company's 2028 annual meeting of stockholders and was not initially assigned to any Board committee. Ms. Appelhans will be compensated under the Company's director compensation program for non-employee directors, as revised from time to time. The filing states that this program currently consists of cash retainers for Board and committee service, restricted stock and stock option awards. The current components were described in the proxy statement for the 2026 Annual Meeting of Stockholders, held on May 5, 2026. The filing states there are no arrangements or understandings under which Ms. Appelhans was elected, and no related person transactions between the Company and her. The filing reports no financial results, guidance, or other operational developments.
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2026
Halozyme Therapeutics, Inc. reported a strong second quarter of 2026, with total revenues of $481.0 million versus $325.7 million in the prior-year quarter, and net income of $229.9 million, or $1.90 per diluted share, compared with $165.2 million, or $1.33 per diluted share, a year earlier. Royalties of $307.7 million rose from $205.6 million, driven by sales uptake of ENHANZE partner products such as VYVGART Hytrulo and DARZALEX SC. Product sales, net increased to $129.6 million, led by bulk rHuPH20 sales of $59.6 million, and revenues under collaborative agreements were $43.7 million, including $35.5 million of upfront license and target nomination fees. Operating income rose to $287.7 million from $202.4 million, although amortization of intangibles, research and development, and SG&A expenses all increased, partly reflecting the Elektrofi and Surf Bio acquisitions completed in late 2025. Capital allocation was a major focus during the quarter. The company repurchased 4.8 million shares for $332.7 million in the second quarter, completed its February 2024 $750.0 million repurchase program in June 2026, and authorized a new program of up to $1.0 billion through December 31, 2028. Cash and cash equivalents were $163.1 million and marketable securities were $67.9 million at June 30, 2026, totaling $231.0 million. Total long-term debt, net, plus the current portion stood at $2.15 billion, consisting mainly of convertible notes, and the revolving credit facility of $750 million was undrawn. Management stated that existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months. The filing also flags a risk tied to the Elektrofi acquisition: a partner is evaluating a potential return of a Hypercon target and will make a decision by February 2027. If the partner returns the target without nominating an alternative with similar future cash flows, the company would need to evaluate its acquired customer relationship intangibles and goodwill, which could lead to a material interim impairment charge. The company also disclosed that it is not party to any legal proceedings expected to have a material adverse effect, while noting litigation costs in connection with a patent infringement case within SG&A.
Halozyme Therapeutics 8-K Report, Financial Results (Aug 6, 2026)
Halozyme Therapeutics, Inc. reported record second-quarter 2026 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Total revenue was $481.0 million, up from $325.7 million in the second quarter of 2025, driven by royalty revenue of $307.7 million (compared with $205.6 million) and higher product sales. Net income was $229.9 million, or $1.90 per diluted share (GAAP), compared with $165.2 million, or $1.33, a year earlier. Non-GAAP diluted EPS was $2.28, compared with $1.54, and adjusted EBITDA was $328.8 million, compared with $225.5 million. The company raised its full-year 2026 guidance. Total revenue is now expected at $1.835 billion to $1.910 billion (previously $1.710 billion to $1.810 billion), royalty revenue at $1.220 billion to $1.245 billion, adjusted EBITDA at $1.225 billion to $1.280 billion, and non-GAAP diluted EPS at $8.65 to $9.00. The guidance includes approximately $60 million of new Hypercon and Surf Bio investments. Management stated that the company has signed five new ENHANZE and Hypercon collaborations year to date, exceeding its goal of three for the full year. On capital allocation, Halozyme repurchased $333 million of shares in the second quarter at an average price of $69.30 under its May 2026 and February 2024 programs. The May 2026 program authorizes up to $1.0 billion of repurchases through December 31, 2028, with an expectation of at least $400 million of buybacks in 2026. Cash, cash equivalents, restricted cash and marketable securities totaled $231.9 million at June 30, 2026, and total debt-related balances on the balance sheet include $209.0 million current and $1.94 billion long-term.
Halozyme Therapeutics 8-K Report, Executive Changes (Jul 2, 2026)
Halozyme Therapeutics, Inc. filed a Current Report on Form 8-K dated June 30, 2026 (filed July 2, 2026) under Item 5.02, which covers departures of directors or certain officers, appointments, and compensatory arrangements. The filing states that on June 30, 2026, the company announced an update to its senior management structure. The same announcement disclosed the departure of Cortney Caudill as Senior Vice President, Chief Operating Officer. The company thanked Ms. Caudill for her contributions during her tenure. The filing does not describe the reasons for the departure, a successor, or any compensation or separation terms. The filing contains no financial results, financial statements, or quantitative figures. It is signed by Darren Snellgrove, Senior Vice President and Chief Financial Officer. For investors, the key item is the leadership change in the operations function and the broader senior management update.
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2026
Halozyme Therapeutics, Inc. reported first-quarter 2026 total revenues of $376.7 million, up from $264.9 million a year earlier, driven primarily by royalties of $240.7 million (versus $168.2 million) and product sales, net of $130.4 million (versus $78.0 million). Net income rose to $150.0 million, or $1.22 per diluted share, compared with $118.1 million, or $0.93 per diluted share, in the prior-year quarter. Royalty growth was led by DARZALEX, VYVGART Hytrulo and Phesgo, and bulk rHuPH20 sales increased to $73.5 million from $27.0 million. Operating expenses rose to $192.2 million from $123.3 million, reflecting cost of sales, amortization tied to the Elektrofi acquisition, higher research and development and higher SG&A. At March 31, 2026, cash and cash equivalents were $309.7 million and cash, cash equivalents and marketable securities totaled $318.6 million. Total debt principal was $2.18 billion across the 2027, 2028, 2031 and 2032 convertible notes, and the $750 million revolving credit facility was undrawn. Net cash provided by operating activities was $180.1 million. The company stated that its current cash and marketable securities will be sufficient to fund operations for at least the next 12 months. Subsequent to quarter end, in May 2026, the Board authorized a new share repurchase program of up to $1 billion through December 31, 2028, with an expectation of buying back at least $400 million of shares in 2026. The filing also discloses new collaborations, including GSK, Oruka and Vertex, and notes that a partner is evaluating a potential target return by September 2026, which could trigger a material interim impairment charge to intangibles and/or goodwill.
Halozyme Therapeutics 8-K Report, Financial Results (May 11, 2026)
Halozyme Therapeutics, Inc. (Nasdaq: HALO) furnished a press release under Item 2.02 reporting first quarter 2026 results for the quarter ended March 31, 2026. Total revenue was $376.7 million, up 42% year over year from $264.9 million, driven by royalty revenue of $240.7 million (up 43% from $168.2 million) and product sales, net, of $130.4 million. GAAP net income was $150.0 million and GAAP diluted EPS was $1.22, compared with $0.93 a year earlier. Non-GAAP diluted EPS was $1.60, versus $1.11. Adjusted EBITDA was $229.5 million, including $11.2 million of intellectual property litigation costs tied to the company's patent case against Merck. Cash, cash equivalents, restricted cash and marketable securities rose to $320.9 million at March 31, 2026, from $145.4 million at December 31, 2025, which the company attributed primarily to operating cash generation. The company reiterated its full-year 2026 guidance: total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, adjusted EBITDA of $1.125 to $1.205 billion, and non-GAAP diluted EPS of $7.75 to $8.25. The guidance includes approximately $60 million of investment related to new Hypercon and Surf Bio activities. The company also announced a new share repurchase program of up to $1 billion of common stock through December 31, 2028, with at least $400 million expected to be repurchased in 2026. The quarter also featured new partnering activity: a Vertex Hypercon agreement with a $15 million upfront payment, a GSK ENHANZE multi-target collaboration, and an Oruka Hypercon agreement. The company also highlighted FDA approval of VYVGART Hytrulo for all serotypes of generalized myasthenia gravis and positive Phase 3 data in ocular myasthenia gravis. The filing notes that results and partner milestones are forward-looking in part and subject to risks described in the company's Form 10-K and Form 10-Q.
Halozyme Therapeutics 8-K Report, Shareholder Vote Results (May 7, 2026)
Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders on May 5, 2026. Of the 118,474,300 shares of common stock outstanding as of the record date, 104,138,244 shares were represented at the meeting. The filing states that stockholders considered three proposals, each described in the Company's definitive proxy statement filed with the SEC on March 23, 2026. Stockholders elected two Class I directors, Bernadette Connaughton and Matthew L. Posard, to three-year terms expiring at the 2029 Annual Meeting. Each received affirmative votes from more than a majority of outstanding shares. Stockholders also approved, on an advisory basis, the compensation of the Company's named executive officers, with 84,682,518 votes for, 9,311,426 against, 255,081 abstentions and 9,889,219 broker non-votes. Stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 103,197,579 votes for, 849,433 against and 91,232 abstentions. The filing reports no broker non-votes for this proposal.
Halozyme Therapeutics 8-K Report, Executive Changes (Apr 30, 2026)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced on April 30, 2026 that Darren Snellgrove has been appointed Chief Financial Officer, effective June 8, 2026, reporting to President and CEO Helen Torley. Mr. Snellgrove, age 52, most recently served as Vice President, Investor Relations at Johnson & Johnson since May 2025, and previously served as CFO of J&J's Pharmaceutical sector from August 2021 to May 2025. David Ramsay, the current Interim CFO, will move to an advisory role effective June 8, 2026 to assist during a brief transition period. Compensation terms include an annual base salary of $670,000, a bonus target of 50% of base salary (prorated in 2026), and a 2027 long-term incentive award with a minimum total grant date value of $4,000,000. On joining, he will receive equity awards with a total grant date value of $7,200,000, consisting of $3,200,000 in restricted stock units intended to make him whole for forfeited equity from J&J, vesting one-third annually over three years, and $4,000,000 in stock options. He will also receive a $350,000 sign-on cash bonus, partially subject to repayment if he leaves or is terminated for misconduct within 24 months. The filing also includes a press release describing the new CFO's responsibilities, which include capital allocation, corporate development and investor relations, and the company's stated aim of accelerating shareholder value creation. The filing reports no family relationships with directors or executive officers and no material related-party interest.
Halozyme Therapeutics 8-K Report, Bylaw Amendment (Apr 24, 2026)
Halozyme Therapeutics, Inc. filed a Current Report on Form 8-K on April 24, 2026 to disclose amendments to its Bylaws adopted by the Board of Directors on April 22, 2026. The filing does not report financial results, financial figures, or operating developments. The first amendment revises Section 2.5 of the Bylaws to provide that directors may be removed from office at any time, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of the directors. The second amendment revises Section 1.12 to clarify that any action required or permitted to be taken at an annual or special meeting of stockholders may not be taken without a meeting, consistent with Article FIFTH of the Certificate of Incorporation. The full amended Bylaws are filed as Exhibit 3.1, and the filing includes the Cover Page Interactive Data File (Exhibit 104) formatted as inline XBRL.
Halozyme Therapeutics 8-K Report, Executive Changes (Mar 12, 2026)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Form 8-K on March 12, 2026 to announce the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO, for which it has engaged a leading executive search firm. He will remain in the role until a permanent CFO is appointed. Mr. Ramsay previously served as the Company's CFO from 2003 to 2009 and again from 2013 to 2015, and as Vice President, Corporate Development from 2009 to 2013. Since April 2017 he has served on the board of Savara Inc., and he was previously Senior Vice President and CFO of Bonti, Inc. until its acquisition by Allergan plc in October 2018. The filing states that he has no family relationships with any director or executive officer and no material interest in any Company transaction. Compensation under the arrangement is a monthly salary of $50,000, plus an initial grant of 10,000 restricted stock units (RSUs) vesting on June 30, 2026, and an additional 2,500 RSUs granted if he is still Interim CFO on July 1, 2026. Both grants fall under the 2021 Stock Plan and carry a one-year holding period after vesting. The filing also notes that the forward-looking statements in the press release cite potential delays in hiring a permanent CFO as a risk factor.
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2025
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $1,396.6 million for 2025, up from $1,015.3 million in 2024, driven primarily by royalties of $867.8 million (up from $571.0 million) and product sales, net of $376.4 million. Revenues under collaborative agreements were $152.3 million. Operating income fell to $469.0 million from $551.5 million, reflecting $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition, a $48.7 million impairment of the ATRS-1902 intangible asset, and higher cost of sales and SG&A. Net income was $316.9 million, or $2.56 per diluted share, compared with $444.1 million, or $3.43, in 2024. Royalty growth was led by DARZALEX SC, VYVGART Hytrulo and Phesgo, and the company said ENHANZE remains its largest revenue driver. The company significantly expanded its balance sheet during the year. It acquired Elektrofi (later renamed Halozyme Hypercon, Inc.) for total consideration of $810.4 million and Surf Bio for $305.0 million, plus up to $100.0 million in contingent milestones. In November 2025 it issued $750.0 million of 0.00% Convertible Notes due 2031 and $750.0 million of 0.875% Convertible Notes due 2032, and used proceeds to repurchase portions of its 2027 and 2028 Convertible Notes. Total long-term debt carrying value was $2,142.6 million at year-end, against cash, cash equivalents and marketable securities of $142.8 million. Stockholders' equity fell to $48.8 million from $363.8 million, largely due to share repurchases and capped call purchases recorded in equity. Management states that current cash and marketable securities are sufficient for at least the next 12 months, and the $750.0 million revolving credit facility was undrawn at year-end. Key risks highlighted in the filing include dependence on partner performance and regulatory approvals, reliance on rHuPH20 supply from contract manufacturers, product liability exposure, a patent infringement lawsuit against Merck over MDASE technology, U.S. drug pricing and tariff policy, and the potential dilution and cash settlement obligations of the convertible notes.
Halozyme Therapeutics 8-K Report, Financial Results (Feb 17, 2026)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release under Item 2.02 reporting fourth-quarter and full-year 2025 results. Full-year total revenue was $1,396.6 million, up 38% from $1,015.3 million in 2024, driven by royalty revenue of $867.8 million (up 52% from $571.0 million) and higher product sales. Net income for the full year was $316.9 million, compared with $444.1 million in 2024. The results include $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition, which drove a fourth-quarter net loss of $141.6 million. Fourth-quarter total revenue was $451.8 million, up 52% from $298.0 million. Full-year GAAP diluted EPS was $2.56 versus $3.43 in 2024, and non-GAAP diluted EPS was $4.15 versus $4.23. The company reported that cash, cash equivalents, restricted cash and marketable securities were $145.4 million at December 31, 2025, compared with $596.1 million a year earlier, mainly reflecting cash used for the Elektrofi and Surf Bio acquisitions and share repurchases, partly offset by net proceeds from $1.5 billion of convertible notes issued in November 2025 (two $750.0 million tranches due 2031 and 2032). The company also amended its credit agreement, raising its revolving facility from $575.0 million to $750.0 million. Halozyme reiterated its 2026 guidance: total revenue of $1.710 to $1.810 billion (22% to 30% growth), royalty revenue of $1.130 to $1.170 billion (30% to 35% growth), adjusted EBITDA of $1.125 to $1.205 billion (71% to 83% growth), and non-GAAP diluted EPS of $7.75 to $8.25 (87% to 99% growth). The guidance includes approximately $60 million of investment related to Hypercon and Surf Bio. Management stated it expects royalty revenue to exceed $1 billion in 2026 and has a "clear line of sight" to more than $2 billion in total revenue by 2028.
Halozyme Therapeutics 8-K Report, Financial Results (Jan 28, 2026)
Halozyme Therapeutics, Inc. (Nasdaq: HALO) furnished an Item 2.02 Form 8-K on January 28, 2026, disclosing preliminary, unaudited 2025 results and raised 2026 and multi-year guidance. For the twelve months ended December 31, 2025, the company estimates total revenue of $1,385 million to $1,400 million, royalty revenue of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. The company states that royalty revenue growth is expected to exceed 50% year over year in 2025, with total revenue growth of 36% to 38% and royalty revenue growth of 51% to 52%. For 2026, Halozyme raised its guidance: total revenue of $1,710 million to $1,810 million (previously $1,430 million to $1,530 million), royalty revenue of $1,130 million to $1,170 million (previously $900 million to $940 million), adjusted EBITDA of $1,125 million to $1,205 million (previously $1,000 million to $1,080 million), and non-GAAP diluted EPS of $7.75 to $8.25 (previously $6.50 to $7.00). The company notes that these figures include approximately $60 million of Hypercon and Surf Bio investment not included in prior guidance. Management said projected 2026 royalty revenue of more than $1 billion is one year earlier than previously projected. The company also disclosed that it acquired Surf Bio, Inc. in December 2025 for an upfront payment of $300 million, plus up to $100 million in milestone payments, for total consideration of up to $400 million. The filing emphasizes that the preliminary 2025 estimates are subject to completion of financial close procedures and may vary materially from the results in the forthcoming Form 10-K. The Item 2.02 information is furnished, not filed.
Halozyme Therapeutics 8-K Report, Executive Changes (Dec 9, 2025)
Halozyme Therapeutics, Inc. disclosed under Item 5.02 that its Compensation Committee approved a one-time performance-based restricted stock unit grant (the "PSU Grant") for Dr. Helen Torley, Chief Executive Officer, on December 4, 2025. The award was made under the Company's 2021 Stock Plan and has a grant date fair value of $10 million, determined under U.S. GAAP using a Monte Carlo valuation model. The grant is intended to retain Dr. Torley and incentivize her to drive growth and profitability during what the filing calls the Company's "next stage of growth." The number of shares that can vest depends on the average closing price of the common stock over 20 consecutive trading days during a four-year performance period following the grant date. Vesting ranges from 50% of the target shares at an average price of $115.00 to 200% at $170.00, with 100% at $130.00 and 150% at $145.00. If the average price never reaches $115.00, no shares will be eligible to vest. Earned shares also require Dr. Torley's continued employment through the fourth anniversary of the grant date, subject to exceptions in the award agreement. The filing states that voluntary resignation or retirement before the vesting date will result in forfeiture of all performance-based vested shares. The full award agreement is to be filed as an exhibit to the Company's Form 10-K for the fiscal year ending December 31, 2025.
Halozyme Therapeutics 8-K Report, Executive Changes (Dec 8, 2025)
Halozyme Therapeutics, Inc. filed this Form 8-K on December 8, 2025 under Item 5.02 to report a board change. On December 4, 2025, James Lang was elected to the Company's Board of Directors. He was elected to the class of directors whose terms end at the 2027 annual meeting of stockholders, and he was not initially assigned to any Board committee. Mr. Lang will be compensated under the Company's director compensation program applicable to all non-employee directors, as revised from time to time. The filing states that this program currently consists of cash retainers for Board and committee service, restricted stock, and stock option awards. The filing refers to the program components as described in the proxy statement for the 2025 Annual Meeting of Stockholders, held on May 1, 2025. The filing states that there are no arrangements or understandings under which Mr. Lang was elected, and no related person transactions between the Company and Mr. Lang. This is a governance update with no financial figures disclosed in the filing.
Halozyme Therapeutics 8-K Report, Executive Changes (Nov 24, 2025)
Halozyme Therapeutics, Inc. disclosed under Item 5.02 that Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue to serve as CFO until the earliest of the hiring of a new chief financial officer, March 30, 2026, or an earlier date set by the Company (the "Separation Date"), and will then depart to pursue a new professional opportunity. The company had previously announced this transition plan. On November 18, 2025, the Company and Ms. LaBrosse entered into a Transition and Release Agreement. Subject to her compliance with its obligations and her execution of a release of claims, she will be eligible for a 2025 annual bonus at 120% of target-level individual performance, a cash severance payment under the Company's Severance Policy for a not-for-cause termination equal to her annual base salary (plus a pro-rated 2026 target bonus if separation occurs in 2026), and enhanced equity and benefits treatment. Specifically, awards that would have vested by February 28, 2026 vest on the Separation Date if separation occurs before that date, vested options get an extended exercise period, unvested options accelerate on a Change in Control within one year after separation, and COBRA coverage costs are covered for one year. The filing states that the full agreement will be filed as an exhibit to the Company's Form 10-K for the year ending December 31, 2025. For investors, the key items are the impending CFO departure, the defined separation timeframe, and the severance and equity terms that define the cost and retention implications of the transition.
Halozyme Therapeutics 8-K Report, Material Agreement (Nov 12, 2025)
Halozyme Therapeutics, Inc. completed its previously announced sale of $1,500.0 million aggregate principal amount of convertible senior notes on November 12, 2025. The offering consisted of $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of 0.875% Convertible Senior Notes due 2032, each including $100.0 million of additional notes purchased through the initial purchasers' option. The company received net proceeds of approximately $1.47 billion, of which about $182.7 million was used to fund capped call transactions, and it paid approximately $1.020 billion in cash, including accrued interest, to repurchase portions of its outstanding 0.25% Convertible Senior Notes due 2027 and 1.00% Convertible Senior Notes due 2028 through privately negotiated transactions. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and potential future note repurchases. The notes are unsecured and rank effectively junior to secured indebtedness and structurally subordinated to liabilities of subsidiaries. The initial conversion rate is 11.4683 shares per $1,000 principal amount, equivalent to a conversion price of approximately $87.20 per share. The company may settle conversions in cash, shares, or a combination at its election. The 2031 notes carry no regular interest, while the 2032 notes pay 0.875% semi-annually beginning May 15, 2026. The company may not redeem the 2031 notes before February 20, 2029, or the 2032 notes before November 20, 2029. The capped call transactions have an initial cap price of $136.78 per share, which the filing states represents a 100% premium over the November 5, 2025 closing price for both series. Investors should note the holder protections in the indentures, including repurchase rights upon a fundamental change and cross-default provisions tied to indebtedness of at least $50.0 million. The notes were sold under Rule 144A to qualified institutional buyers and have not been registered under the Securities Act.
Halozyme Therapeutics 8-K Report, Corporate Update (Nov 7, 2025)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Current Report on Form 8-K on November 7, 2025 to disclose, via Exhibit 99.1, its press release dated November 6, 2025 announcing the pricing of two convertible senior notes offerings. The Company priced $650.0 million aggregate principal amount of 0% convertible senior notes due 2031 (the 2031 Notes) and $650.0 million aggregate principal amount of 0.875% convertible senior notes due 2032 (the 2032 Notes), for a total of $1.3 billion before the initial purchasers' 13-day option to buy up to an additional $100.0 million of each series. The offering is being sold only to qualified institutional buyers under Rule 144A. Both series have an initial conversion rate of 11.4683 shares per $1,000 principal amount, equal to an initial conversion price of approximately $87.20 per share, a conversion premium of approximately 27.5% over the $68.39 closing price on November 6, 2025. The Company will settle conversions in cash and/or shares at its election. The Company expects the net proceeds to be approximately $1.274 billion (or approximately $1.47 billion if the option is exercised in full). It expects to use about $182.7 million for capped call transactions, with a cap price of $136.78 per share (a 100% premium to the reference price), and about $1.020 billion to repurchase portions of its existing 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028 through privately negotiated transactions, with approximately $1.019 billion in cash expected to be paid including accrued interest. The remainder is intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases. The filing notes that the note repurchases and related hedging activity by counterparties could affect the market price of Halozyme's common stock and the Convertible Notes, and could result in a higher effective conversion price. The Company expects the offering to close on November 12, 2025, subject to customary closing conditions.
Halozyme Therapeutics 8-K Report, Material Agreement (Nov 5, 2025)
On November 5, 2025, Halozyme Therapeutics, Inc. entered into Amendment No. 3 to its Credit Agreement dated May 24, 2022. The amendment extended the maturity of the existing revolving credit facility and increased total revolving commitments to $750,000,000. The Amended Revolving Credit Facility matures on the earlier of November 5, 2030 and the Springing Revolver Maturity Date. As of November 5, 2025, after giving effect to the amendment, the company had $0 of outstanding borrowings under the Credit Agreement. The credit agreement requires a maximum consolidated net leverage ratio of 4.50 to 1.00 and a minimum consolidated interest coverage ratio of 3.00 to 1.00, measured at each fiscal quarter end. The net leverage covenant increases by 0.50 to 1.00, to no more than 5.00 to 1.00, for three fiscal quarters after a material acquisition. The same day, the company announced a proposed offering, subject to market conditions, of $650.0 million of convertible senior notes due 2031 and $650.0 million of convertible senior notes due 2032. The initial purchasers also have a 13-day option to buy up to an additional $100.0 million of each series. The notes are senior, unsecured obligations, with the 2031 Notes maturing February 15, 2031 and the 2032 Notes maturing November 15, 2032. The company intends to settle conversions in cash and, where applicable, shares of common stock, at its election. Net proceeds are expected to fund capped call transactions, privately negotiated repurchases of the company's outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028, and general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions. The filing states that the note repurchases and related hedging activity by counterparties could affect the market price of the common stock and the convertible notes, and could result in a higher effective conversion price for the new notes. The filing also notes that the notes have not been registered under the Securities Act and are being offered only to qualified institutional buyers under Rule 144A.
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2025
Halozyme Therapeutics, Inc. reported third-quarter 2025 total revenues of $354.3 million, up from $290.1 million a year earlier, with net income of $175.2 million (diluted EPS $1.43, versus $1.05). Royalties were $236.0 million, up from $155.1 million, driven mainly by VYVGART Hytrulo, DARZALEX SC and Phesgo. For the nine months, total revenues were $944.8 million and net income was $458.5 million, with net cash provided by operating activities of $432.5 million. Cash, cash equivalents and marketable securities totaled $702.0 million at September 30, 2025, and management states these are sufficient to fund operations for at least the next 12 months. The company repurchased $342.4 million of common stock in the nine months under its $750.0 million program, with $92.3 million used in the third tranche as of quarter-end. The 2028 Convertible Notes ($720.0 million principal) were reclassified to current debt because their conditional conversion feature was triggered, and total current liabilities rose to $837.2 million. The filing states that the company agreed in September 2025 to acquire Elektrofi, Inc. for $750 million upfront plus up to three $50 million milestone payments, with closing expected in the fourth quarter of 2025 subject to antitrust review. The company also filed a patent infringement lawsuit against Merck in April 2025 concerning its MDASE technology, and notes that Otter discontinued marketing OTREXUP in August 2025.
Halozyme Therapeutics 8-K Report, Financial Results (Nov 3, 2025)
Halozyme Therapeutics, Inc. reported record third-quarter 2025 results and raised its 2025 financial guidance. Total revenue for the quarter was $354.3 million, up 22% year-over-year from $290.1 million, driven by royalty revenue of $236.0 million, up 52% from $155.1 million. Net income was $175.2 million, compared to $137.0 million a year earlier, and GAAP diluted EPS was $1.43 versus $1.05. Non-GAAP diluted EPS was $1.72, compared to $1.27. Adjusted EBITDA was $248.2 million, compared to $183.6 million in the prior-year quarter. Cash, cash equivalents and marketable securities totaled $702.0 million at September 30, 2025. For full-year 2025, the company now expects total revenue of $1,300 million to $1,375 million, royalty revenue of $850 million to $880 million, adjusted EBITDA of $885 million to $935 million, and non-GAAP diluted EPS of $6.10 to $6.50. These ranges are each raised from the prior guidance issued August 5, 2025. The filing also discloses a CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will remain CFO until the earlier of the hiring of a successor or March 30, 2026, and then depart for a new professional opportunity. The company has begun an external search for her successor. The filing states her departure is not the result of any disagreement with the auditors or the company. The company also disclosed a pending acquisition of Elektrofi, Inc. for $750 million in upfront consideration plus up to three $50 million milestone payments, expected to close in the fourth quarter of 2025.
Halozyme Therapeutics 8-K Report, Regulation FD Disclosure (Oct 14, 2025)
Halozyme Therapeutics, Inc. filed this Form 8-K on October 14, 2025 under Item 7.01 (Regulation FD Disclosure) to publish a position statement (Exhibit 99.1) on CMS's final IPAY 2028 guidance for Medicare Part B price negotiations under the Inflation Reduction Act. The statement covers the company's long-term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE® partner product subcutaneous sales. The information is furnished, not filed, for purposes of Section 18 of the Exchange Act. The company's central message is that the final guidance has zero to minimal impact on its future partner royalties. CMS declined to change its fixed combination drug policy for initial price applicability year 2028 and said it would consider a rulemaking addressing the issue beginning in price applicability year 2029. Halozyme projects zero royalty revenue impact in 2028 and zero to minimal impact in 2029 through 2031 and through at least 2035. The filing attributes these projections to orphan drug exclusions under the One Big Beautiful Bill Act, the potential exclusion of drugs facing biosimilar launches, and the treatment of Darzalex Faspro and Opdivo as orphan-designated products. The statement also cites a 2025 Journal of Medical Economics study reporting Medicare savings from subcutaneous delivery for 5 of 7 biologic drugs compared with intravenous delivery, and an Oncology and Therapy study in which 89.6% of surveyed patients preferred subcutaneous delivery versus 5.5% for IV. The filing describes these as supporting evidence rather than a new financial result.
Halozyme Therapeutics 8-K Report, Executive Changes (Oct 6, 2025)
Halozyme Therapeutics, Inc. filed this Current Report on Form 8-K under Item 5.02, reporting executive leadership changes. On October 1, 2025, Cortney Caudill was appointed Senior Vice President, Chief Operating Officer, effective immediately. She had already served as the Company's Senior Vice President, Chief Operations Officer since October 2023, so the change is a promotion within the existing executive team rather than an external hire. The filing sets out Ms. Caudill's compensation in her new role. Her initial annual base salary as Chief Operating Officer is $600,000, and she is eligible to participate in the Company's executive officer incentive plans with a 2025 bonus target equal to 50% of base salary. She will also receive an equity award valued at $500,000 in connection with the appointment, split 50% stock options and 50% restricted stock units, vesting under the Company's standard four-year schedule. She will be eligible for long-term incentive awards under the Compensation Committee's practices for executive officers. The filing states that Ms. Caudill has no family relationships with any director or executive officer and no direct or indirect material interest in any transaction in which the Company is a participant. Her prior experience includes Aeglea Biotherapeutics, where she most recently served as Chief Product Officer, and several life sciences operational roles from 2002 to 2018.
Halozyme Therapeutics 8-K Report, Material Agreement (Oct 3, 2025)
On September 30, 2025, Halozyme Therapeutics, Inc. entered into an Agreement and Plan of Merger with Elektrofi, Inc., Erraid Merger Sub Inc. (a wholly-owned Halozyme subsidiary), and Shareholder Representative Services LLC, solely in its capacity as Securityholders' Representative. Under the agreement, Merger Sub will merge into Elektrofi, which will survive as a wholly-owned subsidiary of Halozyme. Halozyme will pay aggregate upfront consideration of $750 million in cash, subject to customary adjustments for Elektrofi's debt, cash, transaction expenses and net working capital, plus up to three $50 million milestone payments contingent on three separate product regulatory approvals. A portion of Elektrofi employee stock options will be assumed by Halozyme and converted into options to acquire Halozyme common stock, which will reduce the cash portion of the Merger Consideration. The merger is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes customary termination rights, including if the merger is not consummated within twelve months of the agreement date, subject to a six-month extension in certain circumstances. If the agreement is terminated under certain circumstances, Halozyme must pay Elektrofi a $36 million reverse termination fee in cash. The filing attaches the Merger Agreement as Exhibit 2.1, with schedules omitted under Item 601(a)(5) of Regulation S-K and certain portions omitted under Item 601(b)(2), which Halozyme agrees to furnish to the SEC upon request. The filing also contains customary forward-looking statements, including risks that the transaction may not be consummated on the proposed terms or timing, or that required regulatory approvals may not be obtained or may be delayed.
Halozyme Therapeutics 8-K Report, Regulation FD Disclosure (Oct 1, 2025)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced on October 1, 2025 that it has entered into a definitive agreement to acquire Elektrofi, Inc., a biopharmaceutical company with its Hypercon™ ultra-high concentration microparticle technology for biologics. The agreement, dated as of September 30, 2025, provides for an upfront payment of $750 million plus up to three $50 million milestone payments contingent on three separate product regulatory approvals. Both companies' Boards unanimously approved the transaction. Halozyme expects the deal to close in 4Q 2025, subject to HSR review and other customary conditions, and plans to finance the upfront payment with existing cash and its existing credit facility. Management states the transaction is expected to be less than 5% dilutive to Non-GAAP diluted EPS over the medium term, excluding potential milestone payments, and expects approximately $55 million of incremental operating expense in full-year 2026. Halozyme expects net leverage to rise to approximately 2X net debt-to-EBITDA immediately after closing, with rapid de-leveraging in subsequent quarters. The company reaffirmed its 2025 guidance ranges (last updated August 5, 2025), excluding the accounting treatment of the transaction, including total revenue of $1,275 million to $1,355 million and royalty revenue of $825 million to $860 million. Management frames the deal as a route to long-term royalty growth, with royalty revenue from Elektrofi's partners projected to begin as early as 2030 and intellectual property extending into the 2040s. Up to $275 million in potential development and commercial milestones from Elektrofi's two existing partner products is cited as supporting near-term de-risking, with two partners projected to begin Hypercon™ formulated product clinical development by year end 2026 or earlier.
Halozyme Therapeutics 8-K Report, Financial Results (Aug 5, 2025)
Halozyme Therapeutics, Inc. reported second-quarter 2025 results for the period ended June 30, 2025, with total revenue of $325.7 million, up 41% year over year from $231.4 million. Royalty revenue rose 65% to $205.6 million, driven mainly by DARZALEX SC, VYVGART Hytrulo and Phesgo. Net income was $165.2 million, compared with $93.2 million in the second quarter of 2024, and GAAP diluted EPS was $1.33, compared with $0.72. Adjusted EBITDA was $225.5 million, and Non-GAAP diluted EPS was $1.54. The company raised its full-year 2025 guidance for the second time this year. Total revenue is now expected at $1,275 million to $1,355 million (previously $1,200 million to $1,280 million), royalty revenue at $825 million to $860 million (previously $750 million to $785 million), adjusted EBITDA at $865 million to $915 million (previously $790 million to $840 million), and Non-GAAP diluted EPS at $6.00 to $6.40 (previously $5.30 to $5.70). The guidance reflects tariffs currently in effect. Capital allocation was active in the quarter. The company repurchased a total of $303.4 million of shares in the second quarter, including the $250 million program announced in May, and began a third $250 million tranche under its $750 million authorized program. Cash, cash equivalents and marketable securities were $548.2 million at June 30, 2025. The filing also notes a patent infringement lawsuit filed in April 2025 against Merck Sharp & Dohme Corp. over its MDASE drug delivery technology, with $2.6 million of related litigation costs recognized in the quarter.
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2025
Halozyme Therapeutics, Inc. reported a strong second quarter of 2025 in its Form 10-Q filed August 5, 2025. Total revenues were $325.7 million for the three months ended June 30, 2025, up from $231.4 million a year earlier, and $590.6 million for the six months, up from $427.2 million. Royalties were the main driver at $205.6 million for the quarter (up 65%), reflecting continued uptake of DARZALEX SC, VYVGART Hytrulo and Phesgo. Net income was $165.2 million for the quarter, or $1.33 per diluted share, compared with $93.2 million and $0.72 per diluted share a year earlier. Operating income for the quarter was $202.4 million. The balance sheet shows cash, cash equivalents and marketable securities of $548.2 million as of June 30, 2025, against long-term debt, net, of $1.51 billion, which consists of the 2027 and 2028 convertible notes. Stockholders' equity fell to $332.7 million from $363.8 million at December 31, 2024, largely due to share repurchases. The company repurchased 5.8 million shares in the second quarter for $303.5 million, and the six-month cash flow statement shows $303.5 million of repurchases of common stock. Net cash provided by operating activities was $253.9 million for the six months. The company stated that it believes its current cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next 12 months. The filing also disclosed a patent infringement lawsuit filed in April 2025 against Merck Sharp & Dohme Corp. concerning its MDASE subcutaneous delivery technology, and noted that Merck has challenged certain related U.S. patents in post-grant review proceedings at the PTAB.
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2025
Halozyme Therapeutics, Inc. reported first-quarter 2025 total revenues of $264.9 million, up from $195.9 million in the prior-year quarter, with royalties of $168.2 million (up 39%) as the largest driver. Product sales, net rose to $78.0 million, led by bulk rHuPH20 sales of $27.0 million, and revenues under collaborative agreements were $18.6 million, including a $15.0 million sales-based milestone. Operating income was $141.5 million versus $95.5 million a year earlier, and net income was $118.1 million, or $0.93 per diluted share, compared with $76.8 million, or $0.60 per diluted share. The balance sheet shows cash, cash equivalents and marketable securities of $747.9 million as of March 31, 2025, against long-term debt, net of $1.51 billion, which consists of the 2027 and 2028 convertible notes with total principal of $1.525 billion. Net cash from operating activities was $154.2 million. During the quarter the company completed a $250.0 million accelerated share repurchase, retiring 4.7 million shares at $53.95 per share, and it stated that $500.0 million remained available under the February 2024 program. Management stated that current cash and marketable securities are sufficient to fund operations for at least the next 12 months. The filing also notes subsequent developments, including the April 2025 filing of a patent infringement lawsuit against Merck Sharp & Dohme Corp. over its MDASE technology, and several partner regulatory approvals in Europe and the U.S., such as Janssen's SC RYBREVANT approval in the EU and argenx's FDA approval of a VYVGART Hytrulo prefilled syringe. The company also disclosed that its CEO, Helen Torley, adopted Rule 10b5-1 trading arrangements covering up to 628,492 shares in total.
Halozyme Therapeutics 8-K Report, Financial Results (May 6, 2025)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported financial results for the first quarter ended March 31, 2025, and raised its 2025 financial guidance ranges, as furnished in Exhibit 99.1 under Item 2.02. Total revenue was $264.9 million, up 35% year over year from $195.9 million, driven by royalty revenue of $168.2 million, up 39% from $120.6 million. Net income was $118.1 million versus $76.8 million, GAAP diluted EPS was $0.93 versus $0.60, and non-GAAP diluted EPS was $1.11 versus $0.79. Adjusted EBITDA was $162.0 million versus $115.7 million in the prior-year quarter. The company raised full-year 2025 guidance: total revenue of $1,200 million to $1,280 million (previously $1,150 million to $1,225 million), royalty revenue of $750 million to $785 million (previously $725 million to $750 million), adjusted EBITDA of $790 million to $840 million (previously $755 million to $805 million), and non-GAAP diluted EPS of $5.30 to $5.70 (previously $4.95 to $5.35). The guidance reflects tariffs currently implemented. The company also announced a second $250 million share repurchase under its $750 million program approved in February 2024, following the first $250 million accelerated share repurchase completed in March 2025. Cash, cash equivalents and marketable securities were $747.9 million at March 31, 2025. The filing also disclosed an April 2025 patent infringement lawsuit against Merck Sharp & Dohme Corp. in the U.S. District Court in New Jersey, alleging that Merck is using Halozyme's MDASE technology to develop subcutaneous Keytruda, and seeking damages and injunctive relief. Partner activity included several ENHANZE-related regulatory and commercial milestones, including FDA approval of VYVGART Hytrulo prefilled syringe for self-injection and a European Commission marketing authorization for SC RYBREVANT with ENHANZE, described as the 10th partner product with ENHANZE to be commercialized.
Halozyme Therapeutics 8-K Report, Shareholder Vote Results (May 2, 2025)
Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders on May 1, 2025. Of the 123,533,310 shares of common stock outstanding as of the record date, 112,767,003 were represented at the meeting. Stockholders considered three proposals, each described in the company's definitive proxy statement filed with the SEC on March 18, 2025. Stockholders elected two Class III directors, Jeffrey W. Henderson and Helen I. Torley, to three-year terms expiring at the 2028 Annual Meeting. Henderson received 98,993,463 votes for and 3,298,117 against. Torley received 101,477,199 votes for and 816,675 against. Each director received affirmative votes from more than a majority of the outstanding shares. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 98,252,464 votes for and 3,966,034 against. In addition, they ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 112,028,211 votes for and 659,976 against. The filing reports voting results only. It does not describe any new corporate actions, financial results, or changes in governance beyond the matters voted on.
Halozyme Therapeutics 8-K Report, Executive Changes (Mar 21, 2025)
Halozyme Therapeutics, Inc. filed this Form 8-K to report a leadership change. On March 17, 2025, Michael J. LaBarre, Senior Vice President and Chief Technical Officer, notified the Company of his decision to retire, effective March 17, 2025. The Company thanked Mr. LaBarre for his many years of service and contributions to the Company's ENHANZE drug delivery technology. The filing is limited to this Item 5.02 disclosure (departure of certain officers). It does not disclose a successor appointment, financial results, or any financial figures, and it contains no financial metrics for investors to evaluate. For investors, the principal takeaway is the departure of a senior technical executive whose tenure was tied to the ENHANZE technology platform. The filing itself does not state any impact on operations, guidance, or succession plans.
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $1,015,324 thousand ($1.02 billion) for 2024, up from $829,253 thousand in 2023. Royalties were $570,991 thousand, product sales, net were $303,492 thousand, and revenues under collaborative agreements were $140,841 thousand. Net income rose to $444,091 thousand from $281,594 thousand, and diluted EPS was $3.43 versus $2.10. ENHANZE, the company's rHuPH20-based subcutaneous drug delivery technology, is the largest revenue driver, and the company has eleven collaborations with nine currently approved partner products. The balance sheet at December 31, 2024 showed cash, cash equivalents and marketable securities of $596.1 million, against consolidated debt carrying value of $1,505.8 million, including $805.0 million of 0.25% convertible notes due 2027 and $720.0 million of 1.00% convertible notes due 2028. Management states these resources are sufficient to fund operations for at least the next 12 months. During 2024 the company repurchased $250.0 million of stock under an accelerated share repurchase agreement, and it has $500.0 million remaining under a $750.0 million program authorized in February 2024. The filing highlights concentration and execution risks. Partner A accounted for 41% of 2024 total revenues and Partner B for 17%. Revenue growth was driven largely by milestone timing and royalty growth from partner products such as DARZALEX SC and Phesgo. Key risks include reliance on partners' regulatory approvals and commercialization, single-source bulk rHuPH20 manufacturing, and an FDA Complete Response Letter received by Janssen in December 2024 for SC amivantamab.
Halozyme Therapeutics 8-K Report, Financial Results (Feb 18, 2025)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported fourth-quarter and full-year 2024 results in a press release furnished as Exhibit 99.1 under Item 2.02 of this 8-K, dated February 18, 2025. Total revenue for the fourth quarter was $298.0 million, up from $230.0 million a year earlier, driven by royalty revenue of $170.4 million (up 40% from $122.1 million) and higher collaborative-agreement revenue. For full-year 2024, total revenue was $1,015.3 million versus $829.3 million in 2023, and royalties were $571.0 million versus $447.9 million. Net income for the full year was $444.1 million and GAAP diluted EPS was $3.43; non-GAAP diluted EPS was $4.23. Adjusted EBITDA for the year was $632.2 million, compared with $426.2 million in 2023. The company reiterated its 2025 guidance, first given January 8, 2025: total revenue of $1,150 million to $1,225 million, royalty revenue of $725 million to $750 million, adjusted EBITDA of $755 million to $805 million, and non-GAAP diluted EPS of $4.95 to $5.35. Management said VYVGART Hytrulo is expected to become the largest dollar growth contributor to royalties in 2025. The company also noted four ENHANZE approvals in the U.S. and EU during 2024, five new ENHANZE nominations, a European ENHANZE patent extension to 2029, and an accelerated share repurchase of $250.0 million entered into in December 2024 under a $750 million program. At December 31, 2024, cash, cash equivalents and marketable securities totaled $596.1 million, up from $336.0 million at year-end 2023, and total stockholders' equity was $363.8 million. Long-term debt, net, was $1,505.8 million. The company said the increase in cash was primarily a result of cash generated from operations.
Halozyme Therapeutics 8-K Report, Executive Changes (Feb 13, 2025)
Halozyme Therapeutics, Inc. reported in this Form 8-K, filed February 13, 2025, that director Connie L. Matsui notified the Company on February 11, 2025, of her intention not to stand for reelection at the Company's 2025 annual meeting of stockholders. The filing is limited to this board change under Item 5.02(b), and it contains no financial results, guidance, or other operational or strategic disclosures. The Company and its Board of Directors thanked Ms. Matsui for her nearly 18 years of service, describing her counsel as sage advice. The filing states that her decision was not the result of any disagreement with the Company, any matter related to its operations, policies, practices or strategy, its management, or the Board. For investors, the disclosure is a routine board transition with no stated financial impact. It signals a board seat that will open after the 2025 annual meeting, and the filing does not name a successor or describe any related compensation arrangements.
Halozyme Therapeutics 8-K Report, Financial Results (Jan 8, 2025)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release dated January 8, 2025 under Item 2.02 reiterating its 2024 financial guidance and raising its 2025 and multi-year guidance. The company's preliminary, unaudited 2024 estimates show total revenue of $970 to $1,020 million, royalty revenue of $550 to $565 million, net income of $419 to $443 million, adjusted EBITDA of $595 to $625 million, GAAP diluted EPS of $3.22 to $3.40, and non-GAAP diluted EPS of $4.00 to $4.20. The company notes these estimates are subject to completion of its financial close and could vary materially from final results in its Form 10-K. For 2025, Halozyme raised its guidance ranges: total revenue of $1,150 million to $1,225 million (16% to 23% growth over projected 2024), royalty revenue of $725 million to $750 million (30% to 35% growth), adjusted EBITDA of $755 million to $805 million (24% to 32% growth), and non-GAAP diluted EPS of $4.95 to $5.35 (21% to 30% growth). Prior 2025 ranges were total revenue of $1,095 million to $1,170 million, royalty revenue of $650 million to $675 million, adjusted EBITDA of $710 million to $760 million, and non-GAAP diluted EPS of $4.45 to $4.85. The company attributes the outlook mainly to VYVGART Hytrulo, Darzalex SC and Phesgo, with Ocrevus Zunovo, Tecentriq Hybreza and Opdivo Qvantig expected to contribute modestly in 2025. The company also announced a new $250 million accelerated share repurchase program under its previously announced $750 million share repurchase program. The 2025 EPS guidance does not consider the impact of potential future share repurchases.
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2024
Halozyme Therapeutics, Inc. reported third-quarter 2024 results in this Form 10-Q filed October 31, 2024. Total revenues for the three months ended September 30, 2024 were $290.1 million, up from $216.0 million a year earlier, and net income was $137.0 million, or $1.05 per diluted share, compared with $81.8 million, or $0.61 per diluted share, in the prior-year quarter. Royalties rose to $155.1 million from $114.4 million, driven by sales uptake of DARZALEX SC by Janssen and Phesgo by Roche, and revenues under collaborative agreements increased to $48.4 million, including a $27.0 million upfront license and target nomination fee. For the nine months ended September 30, 2024, total revenues were $717.3 million and net income was $307.1 million. At September 30, 2024, cash, cash equivalents and marketable securities totaled $666.3 million, and the company stated this is sufficient to fund operations for at least the next twelve months. Total assets were $2.12 billion and total stockholders' equity was $452.7 million, compared with $83.8 million at December 31, 2023. Long-term debt, net was $1.50 billion, consisting of the 0.25% Convertible Notes due 2027 and the 1.00% Convertible Notes due 2028, both with principal of $1.525 billion in total. Net cash provided by operating activities for the nine months was $300.6 million. The company completed a $750.0 million capital return program in June 2024 and authorized a new $750.0 million repurchase program in February 2024; no shares were repurchased in the third quarter of 2024. The filing also highlights recent partner milestones, including the September 2024 expansion of argenx's collaboration to six targets with $30.0 million in upfront payments, FDA approval of OCREVUS ZUNOVO with ENHANZE, and FDA approval of TECENTRIQ HYBREZA with ENHANZE, which resulted in a $12.0 million milestone payment. The company states that it is not a party to any legal proceedings expected to have a material adverse effect.
Halozyme Therapeutics 8-K Report, Financial Results (Oct 31, 2024)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release dated October 31, 2024 (Exhibit 99.1) reporting third quarter 2024 results for the period ended September 30, 2024. Total revenue rose 34% year over year to $290.1 million, driven by royalty revenue growth and higher milestone revenue. Royalties were $155.1 million, up 36% from $114.4 million, primarily from DARZALEX SC, Phesgo and the prior-year launch of VYVGART Hytrulo. Net income was $137.0 million versus $81.8 million, GAAP diluted EPS was $1.05 versus $0.61, and non-GAAP diluted EPS was $1.27 versus $0.75. Adjusted EBITDA was $183.6 million versus $114.9 million a year earlier. The company raised its 2024 guidance ranges: total revenue of $970 million to $1,020 million (previously $935 million to $1,015 million), royalty revenue of $550 million to $565 million (previously $520 million to $555 million), adjusted EBITDA of $595 million to $625 million (previously $555 million to $615 million), and non-GAAP diluted EPS of $4.00 to $4.20 (previously $3.65 to $4.05). Cash, cash equivalents and marketable securities were $666.3 million at September 30, 2024, compared with $336.0 million at December 31, 2023. For partner activity, the release notes that argenx expanded its license agreement in September 2024 to four additional targets, for a total of six, with upfront payments of $7.5 million per target ($30.0 million total). ViiV added one undisclosed target, and the FDA approved OCREVUS ZUNOVO and TECENTRIQ HYBREZA with ENHANZE in September 2024.
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2024
Halozyme Therapeutics, Inc. reported second-quarter 2024 total revenues of $231.4 million, up from $221.0 million in the prior-year quarter, and net income of $93.2 million, or $0.72 per diluted share, versus $74.8 million, or $0.56 per diluted share, a year earlier. Royalties rose to $124.9 million from $111.7 million, driven by continued uptake of Phesgo by Roche and the recent launches of VYVGART Hytrulo by argenx and Teriparatide by Teva in the U.S. Proprietary product sales grew to $44.1 million from $32.3 million, while bulk rHuPH20 sales and device partnered product sales declined on timing of partner demand. Revenues under collaborative agreements fell to $27.5 million from $35.4 million, which management attributed to the timing of milestones achieved. For the first six months of 2024, total revenues were $427.2 million and net income was $170.1 million, or $1.32 per diluted share. Cash, cash equivalents and marketable securities totaled $529.0 million at June 30, 2024, and the company stated these balances are sufficient to fund operations for at least the next twelve months. Net cash provided by operating activities was $185.2 million for the six months. The company completed its December 2021 $750.0 million share repurchase program in June 2024 and authorized a new $750.0 million program in February 2024. Long-term debt, net, was $1.50 billion, consisting of the 0.25% Convertible Notes due 2027 and the 1.00% Convertible Notes due 2028. Management noted that the company expects royalty revenue to grow as partner product sales of DARZALEX SC and Phesgo increase and as recently launched partner products, including VYVGART Hytrulo, Tecentriq SC and Ocrevus SC, ramp. The filing also states that a newly issued European patent maintains the original royalty rate on DARZALEX SC sales in 37 European countries until March 2029, and that the company is not party to any legal proceedings expected to have a material adverse effect.
Halozyme Therapeutics 8-K Report, Financial Results (Aug 6, 2024)
Halozyme Therapeutics, Inc. furnished a press release (Exhibit 99.1) reporting second-quarter 2024 results for the period ended June 30, 2024. Total revenue was $231.4 million, up 5% from $221.0 million a year earlier. Royalty revenue rose 12% to $124.9 million, driven by Phesgo, the launch of VYVGART Hytrulo and the U.S. launch of Teriparatide. Net income was $93.2 million, compared with $74.8 million, and GAAP diluted EPS was $0.72 versus $0.56. Adjusted EBITDA was $137.0 million, compared with $115.1 million, and non-GAAP diluted EPS was $0.91 versus $0.74. Cash, cash equivalents and marketable securities totaled $529.0 million at June 30, 2024, up from $336.0 million at December 31, 2023. The company reiterated its 2024 guidance, which was raised on June 6, 2024 following a new European patent covering the ENHANZE rHuPH20 product. Guidance calls for total revenue of $935 million to $1,015 million (13% to 22% growth), royalty revenue of $520 million to $555 million (16% to 24% growth), adjusted EBITDA of $555 million to $615 million (30% to 44% growth) and non-GAAP diluted EPS of $3.65 to $4.05 (32% to 46% growth). The new European patent maintains the original royalty rate on DARZALEX SC sales in 37 European countries until March 2029. Royalties on DARZALEX SC were temporarily lowered in Europe between March and June 2024 before the patent was issued. The company also completed a $250 million accelerated share repurchase in June 2024, retiring 6.5 million shares at $38.35 per share, which concluded a December 2021 program totaling 19.1 million shares repurchased at an average of $39.31 per share. Management pointed to upcoming partner regulatory events, including a PDUFA goal date of September 13, 2024 for Roche's ocrelizumab SC and a PDUFA goal date of December 29, 2024 for BMS's nivolumab SC.
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2024
Halozyme Therapeutics, Inc. reported first-quarter 2024 total revenues of $195.9 million, up from $162.1 million in the prior-year quarter, and net income of $76.8 million, or $0.60 per diluted share, compared with $39.6 million, or $0.29 per diluted share, a year earlier. Royalties rose to $120.6 million from $99.6 million, driven primarily by continued uptake of DARZALEX SC by Janssen and Phesgo by Roche and the launch of Vyvgart by argenx. Revenues under collaborative agreements increased to $16.7 million, including $14.0 million in event-based development and regulatory milestones. Product sales, net declined to $58.6 million from $60.8 million, mainly due to lower bulk rHuPH20 sales from the timing of shipments to partners, partially offset by growth in proprietary product sales of $35.3 million. The balance sheet strengthened, with cash, cash equivalents and marketable securities totaling $463.5 million at March 31, 2024, and stockholders' equity rising to $177.8 million from $83.8 million at December 31, 2023. Operating cash flow was $129.4 million, compared with $86.96 million a year earlier. Long-term debt, net was $1.50 billion, consisting of the 2027 and 2028 Convertible Notes, and the $575 million revolving credit facility was undrawn. The company repurchased no shares in the quarter, and in February 2024 its board authorized a new $750.0 million capital return program. Management stated that the company believes its cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next twelve months. The filing notes expected fluctuations in collaborative and bulk rHuPH20 revenues tied to partner milestones and shipment timing, and recent partner regulatory milestones, including a $15.0 million milestone tied to the FDA's acceptance of BMS's Opdivo SC BLA.
Halozyme Therapeutics 8-K Report, Financial Results (May 7, 2024)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported first quarter 2024 results on May 7, 2024, as furnished in Exhibit 99.1 under Item 2.02. Total revenues were $195.9 million, up from $162.1 million in the first quarter of 2023, driven by royalty revenue of $120.6 million and higher milestone revenue. Net income was $76.8 million, or $0.60 GAAP diluted EPS, compared with $39.6 million, or $0.29, a year earlier. Non-GAAP diluted EPS was $0.79 versus $0.47, and EBITDA and Adjusted EBITDA were both $115.7 million versus $74.3 million. The company reiterated its 2024 guidance: total revenue of $915 million to $985 million, royalty revenue of $500 million to $525 million, Adjusted EBITDA of $535 million to $585 million, and Non-GAAP diluted EPS of $3.55 to $3.90. Cash, cash equivalents and marketable securities were $463.5 million at March 31, 2024, up from $336.0 million at December 31, 2023, which the company attributed primarily to cash generated from operations. Total stockholders' equity rose to $177.8 million from $83.8 million. Management highlighted partner milestones, including FDA acceptance of Bristol Myers Squibb's subcutaneous nivolumab with a PDUFA goal date of February 28, 2025 and a $15.0 million milestone payment, and argenx's VYVDURA approval in Japan with $14.0 million in total milestone payments. The company also referenced a $750 million share repurchase program announced in February 2024.
Halozyme Therapeutics 8-K Report, Shareholder Vote Results (Apr 26, 2024)
On April 25, 2024, Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders, at which 115,681,780 of the 127,054,240 shares of common stock outstanding as of the record date were represented. Stockholders elected two Class II directors, Barbara Duncan and Mahesh Krishnan, M.D., to three-year terms expiring at the 2027 Annual Meeting. Duncan received 90,120,424 votes for and 15,016,536 against, while Krishnan received 103,968,663 votes for and 1,164,017 against. Dr. Krishnan was subsequently appointed by the Board to the Nominating and Corporate Governance Committee. Stockholders also approved three other proposals: an advisory vote on named executive officer compensation (102,860,435 for, 2,190,603 against), an amendment to the Amended and Restated Certificate of Incorporation reflecting Delaware law provisions on officer exculpation (91,512,252 for, 13,612,616 against), and the ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 (114,912,469 for, 647,868 against). The exculpation amendment became effective upon filing the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on April 25, 2024, a copy of which is filed as Exhibit 3.1. The filing is a routine governance disclosure. It reports the results of shareholder votes and a charter amendment, and it contains no financial results, guidance, or transaction disclosures. Details of each proposal are described in the company's definitive proxy statement filed March 15, 2024.
Halozyme Therapeutics 8-K Report, Financial Results (Feb 20, 2024)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported fourth quarter and full year 2023 results in a press release furnished as Exhibit 99.1 to this Item 2.02 filing. Fourth quarter 2023 total revenue was $230.0 million, up 27% year-over-year from $181.5 million, driven by royalty revenue of $122.1 million, higher bulk rHuPH20 sales, XYOSTED growth and higher milestone revenue. Full year 2023 total revenue was $829.3 million, up 26% from $660.1 million, and GAAP diluted EPS was $2.10 versus $1.44 in 2022, while non-GAAP diluted EPS was $2.77 versus $2.21. Full year 2023 net income was $281.6 million and operating income was $337.6 million. The company reiterated its 2024 guidance, issued January 17, 2024: total revenue of $915 million to $985 million, royalty revenue of $500 million to $525 million, adjusted EBITDA of $535 million to $585 million, and non-GAAP diluted EPS of $3.55 to $3.90. Management cited 2023 approvals and positive phase 3 readouts, including VYVGART Hytrulo in CIDP and subcutaneous ocrelizumab and nivolumab, as drivers of future revenue opportunities. Cash, cash equivalents and marketable securities totaled $336.0 million at December 31, 2023, down from $362.8 million a year earlier, mainly due to $400.0 million of share repurchases in 2023. The filing also discloses a new share repurchase program of up to $750 million, announced in February 2024, which follows an accelerated share repurchase agreement entered in November 2023 to complete the remaining $250.0 million of a prior $750 million program. The company's total stockholders' equity fell to $83.8 million at year-end 2023 from $169.8 million, and long-term debt, net, was $1.50 billion.
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2023
Halozyme Therapeutics, Inc. reported full-year 2023 total revenues of $829.3 million, up from $660.1 million in 2022, with net income of $281.6 million (diluted EPS $2.10) compared with $202.1 million in 2022. Royalties rose to $447.9 million from $360.5 million, driven by continued uptake of DARZALEX SC by Janssen and Phesgo by Roche and new device royalties from the Antares acquisition. Total product sales, net, increased to $300.9 million from $191.0 million, led by proprietary products (XYOSTED and Hylenex) and bulk rHuPH20 sales. Revenues under collaborative agreements declined to $80.5 million from $108.6 million, reflecting the timing of milestones. The company's balance sheet carries $1,499.2 million of net long-term debt, consisting of 2027 and 2028 Convertible Notes with total principal of $1,525.0 million, against cash, cash equivalents and marketable securities of $336.0 million. Management states these resources are sufficient to fund operations for at least the next 12 months. Stockholders' equity fell to $83.8 million from $169.8 million, largely due to $402.4 million of share repurchases in 2023. In February 2024, the board authorized a new $750.0 million capital return program. Key risks highlighted include dependence on partners' regulatory approvals and commercialization, reliance on rHuPH20 as the core technology underlying most ENHANZE revenues, single-source contract manufacturers for bulk rHuPH20, and the Alexion and Horizon collaboration terminations effective in 2024. Customer concentration is significant, with one partner accounting for 44% of 2023 total revenues.